Predict your next investment

Venture Capital
cmea.com

See what CB Insights has to offer

Investments

7

Portfolio Exits

4

About CMEA Capital

CMEA Capital is a venture capital firm located in San Francisco, California. CMEA Capital provides capital to entrepreneurs in the energy & materials, information technology, and life science sectors.

CMEA Capital Headquarter Location

1 Letterman Drive Building C, Suite CM500

San Francisco, California, 94129,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing CMEA Capital

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find CMEA Capital in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

CMEA Capital Investments

7 Investments

CMEA Capital has made 7 investments. Their latest investment was in Neos Therapeutics as part of their Series C - II on March 3, 2014.

CBI Logo

CMEA Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/4/2014

Series C - II

Neos Therapeutics

$15.5M

Yes

4

4/13/2009

Series E - II

Subscribe to see more

$99M

Subscribe to see more

10

12/26/2001

Series D

Subscribe to see more

$99M

Subscribe to see more

10

1/1/2001

Series C

Subscribe to see more

$99M

Subscribe to see more

10

10/3/2000

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/4/2014

4/13/2009

12/26/2001

1/1/2001

10/3/2000

Round

Series C - II

Series E - II

Series D

Series C

Series B

Company

Neos Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$15.5M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

10

10

10

10

CMEA Capital Portfolio Exits

4 Portfolio Exits

CMEA Capital has 4 portfolio exits. Their latest portfolio exit was Neos Therapeutics on July 23, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/23/2015

IPO

$991

1

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

7/23/2015

00/00/0000

00/00/0000

00/00/0000

Exit

IPO

Subscribe to see more

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

CMEA Capital Team

3 Team Members

CMEA Capital has 3 team members, including former Managing Director, David J Collier.

Name

Work History

Title

Status

Thomas R. Baruch

Founder

Current

David J Collier

Presidio Partners, Menlo Therapeutics, and Burrill & Company

Managing Director

Former

Faysal Sohail

General Partner

Former

Name

Thomas R. Baruch

David J Collier

Faysal Sohail

Work History

Presidio Partners, Menlo Therapeutics, and Burrill & Company

Title

Founder

Managing Director

General Partner

Status

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.